BioSpace News Archive

NANO-X IMAGING LTD (www.nanox.vision) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces it has signed an exclusive distribution agreement with Golden Vine International (廖佩玲) (“Golden Vine”), for the introduction of affordable advanced medical imaging services in Taiwan and Singapore.

MTF Biologics, a global nonprofit organization that saves and heals lives through advancing tissue and organ donation, transplantation, and research, today announced that new positive coverage decisions by Aetna, Centene Corporation, WellCare and Tufts Health Plan will provide greater access to its human placental and dermal allografts, AmnioBand® and AlloPatch®, for the treatment of diabetic foot ulcers (DFUs).

Proof of concept for novel oncolytic virus with differentiated anti-CTLA4 antibody Significant antitumor activity of BT-001 seen in several immunocompetent models Treatment with BT-001 also induced a specific and long-lasting immune memory, which is thought to act on distant tumors and to prevent potential relapse Phase I clinical trial with BT-001 expected to start before the end of 2020 Data presented at AACR Virtual

Altasciences announced today the appointment of Dr. Joseph A. Francisco as Chief Toxicologist, effective June 22, 2020.

BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene

AveXis, a Novartis company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization of Zolgensma® (onasemnogene abeparvovec).

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4

- Preclinical data for lead candidate and local activation therapy presented in a poster at AACR - - IND clearance has been received from the FDA to initiate a Phase 1 clinical study of SQ3370 - SAN FRANCISCO--( BUSINESS WIRE )-- Shasqi, a leader in chemistry based locally-activated cancer drugs, today presented data showing that the company’s lead candidate SQ3370 produced robust anti-tumor responses both at the target site and at distal lesi

AveXis, a Novartis company, today announced that new data from the Phase 1/2 STRONG study demonstrated a one-time intrathecal (IT) administration of AVXS-101 in patients ≥2 years and <5 years old with spinal muscular atrophy (SMA) Type 2 who received Dose B (1.2 x 1014 vg) met the primary efficacy endpoint.

Ambra Health , makers of the leading cloud-based, medical image management suite, today announced further integration with Epic to enable medical imaging in desktop, mobile and web applications. Th